evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,062 questions · 1,113 findings · 171 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 161 · 14.5%GRADE not reported 41 · 3.7%Very low 269 · 24.2%Low 321 · 28.8%Moderate 252 · 22.6%High 69 · 6.2%

Ocrelizumab vs interferon beta‐1a

Relapse · patients with relapsing‐remitting multiple sclerosis

Ocrelizumab probably leads to lower number of participants experiencing ≥ 1 relapse compared with interferon beta‐1a (moderate certainty).

1 finding from 1 review

Ocrelizumab vs placebo

Number of participants with any serious adverse events · primary progressive multiple sclerosis

Ocrelizumab showed no clear difference in number of participants with any serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Ocrelizumab vs placebo

Number of adverse events requiring discontinuation of treatment ‐ not reported · primary progressive multiple sclerosis

Ocrelizumab showed no clear difference in number of participants experiencing treatment discontinuation caused… compared with placebo (low certainty).

1 finding from 1 review

Ocrelizumab vs placebo

Number of participants with gadolinium‐enhancing T1 lesions on MRI · primary progressive multiple sclerosis

The review found no eligible studies for this question.

1 finding from 1 review

Ocrelizumab vs placebo

Number of participants with new or enlarging T2‐hyperintense lesions on MRI · primary progressive multiple sclerosis

The review found no eligible studies for this question.

1 finding from 1 review

Ocrelizumab vs interferon beta‐1a

Number of participants experiencing disability progression · patients with relapsing‐remitting multiple sclerosis

Ocrelizumab may leads to lower number of participants experiencing disability progression compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Ocrelizumab vs interferon beta‐1a

Number of participants with any adverse events · patients with relapsing‐remitting multiple sclerosis

Ocrelizumab showed no clear difference in number of participants with any adverse events compared with interferon beta‐1a (moderate certainty).

1 finding from 1 review

Ocrelizumab vs interferon beta‐1a

Number of participants with any serious adverse events · patients with relapsing‐remitting multiple sclerosis

Ocrelizumab showed no clear difference in number of participants with any serious adverse events compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Ocrelizumab vs interferon beta‐1a

Number of participants with adverse events leading to study discontinuation · patients with relapsing‐remitting multiple sclerosis

Ocrelizumab may leads to lower number of participants experiencing treatment discontinuation caused… compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Ocrelizumab vs interferon beta‐1a

Number of participants with gadolinium‐enhancing T1 lesions on MRI · patients with relapsing‐remitting multiple sclerosis

Ocrelizumab may leads to lower number of participants with gadolinium‐enhancing T1 lesions on MRI compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Ocrelizumab vs interferon beta‐1a

Number of participants with new or enlarging T2‐hyperintense lesions on MRI · patients with relapsing‐remitting multiple sclerosis

Ocrelizumab may leads to lower number of participants with new or enlarging T2‐hyperintense lesions… compared with interferon beta‐1a (low certainty).

1 finding from 1 review